Harvard Bioscience (HBIO) Q3 2026 earnings review
Harvard Bioscience sales rise 8%, but it cuts profit plans
Harvard Bioscience, a maker of drug-research laboratory instruments, grew sales for a second quarter while its profitability shrank. Third-quarter revenue rose 8% from a year ago as chief executive John Duke cited rebounding demand from Chinese customers and contract research labs. However, gross margin excluding one-offs dropped 2.1 percentage points because buyers ordered cheaper cellular gear and bought more through distributors, which pushed profit down 11%.
| Revenue | $22.2M +7.8% from a year ago |
|---|---|
| Gross margin, excluding one-offs | 57.1% 59.2% a year ago |
| EBITDA, excluding one-offs | $1.76M -11.3% from a year ago |
| Full-year EBITDA growth outlook | Cut to -1% to +4% prior plan: +6% to +10% |
⚖️ Verdict: 🔴 Bearish
The story got worse because top-line growth is failing to lift profit or stop the cash drain. Management cut its full-year EBITDA growth plan from a range of 6%–10% down to between -1% and +4%, while quarterly interest costs topped operating profit and cash fell to $4.9 million. On the positive side, the Massachusetts factory closure stays on schedule for early 2027.
The question now is whether rising sales of newer organoid and cell-testing tools can actually expand margins, or if lower-margin distributor and China sales will keep eating up the gains. If new products take over, fourth-quarter gross margin excluding one-offs will rebound to the 59% to 61% plan; if mix pressure persists, the company will miss its year-end profit target and further strain its thin cash cushion. Fourth-quarter results and the 2027 factory exit will settle it.
🐂 Bull Case
China and Contract Research Carry Revenue Growth
Harvard Bioscience makes laboratory instruments and testing gear for drug research. After six straight quarters of shrinking sales in 2024 and 2025, chief executive John Duke said the group "delivered our second consecutive quarter of strong year over year growth with an 8% topline increase in the third quarter".
Sales reached $22.2 million, landing in the upper half of the company's $21.0 million to $22.6 million plan. Duke pointed to "solid double-digit revenue growth to CROs and customers in China, driven by sales of our products for organoids, respiratory, and fluidics products", where CROs are contract research organizations that run outsourced drug trials. That rebound matters because Chinese tariff disruptions hurt sales a year ago, and localized BTX cell-analysis production is now winning back orders.
What to watch: regional revenue tables in the quarterly filing. Those numbers will show whether US academic demand is also recovering or if growth rests only on China lapping last year's weak quarter.
Project Viking Factory Consolidation Stays on Schedule
The laboratory tools maker is closing its headquarters factory in Holliston, Massachusetts, and moving production to Minneapolis and Europe under a restructuring plan called Project Viking. The company expects the move to save about $3 million in 2027 and $4 million a year from 2028.
Duke said "Project Viking remains on track for completion by the end of the first quarter in 2027". The business booked $1.67 million of restructuring charges across cost of sales and operating expenses this quarter to fund the transition. Keeping the schedule intact matters because next year's profit recovery depends on dropping those duplicate factory costs.
What to watch: confirmation on the conference call that the group moved two more product lines out of Holliston during the third quarter. Any delay past the first quarter of 2027 would push out the $3 million cost savings.
🐻 Bear Case
Unfavorable Product Mix Forces a Profit Cut
Management has argued for three quarters that New Product Innovation (NPI), its newest instruments for organoid and cell research, carries higher margins and will lift company profitability. That pitch serves as a strengthening driver for top-line adoption and a persistent risk on margins. This quarter's numbers backed the risk.
- Gross margin excluding one-offs: 57.1%, down 2.1 percentage points from 59.2% a year ago
- Cost of making products: 44.6% of revenue, up 2.9 percentage points from a year ago
- Sales and marketing costs: 24.4% of revenue, up 2.0 percentage points
- Full-year EBITDA growth plan, excluding one-offs: cut from 6%–10% to between -1% and +4%
Even though revenue beat the middle of the quarterly outlook, EBITDA excluding one-offs fell 11.3% from a year ago to $1.76 million. Harvard Bioscience cut its full-year profit target because of "higher-than-expected sales of certain lower-margin CMT products and higher revenue contribution from distribution channels and China", where CMT is Cellular and Molecular Technology lab equipment. Growing through Chinese distributors and older cellular gear dilutes profitability faster than new products can lift it.
What to watch: NPI's exact share of third-quarter revenue on the earnings call, compared against 11% in the second quarter. A flat or lower share would show that low-margin distributor sales are driving the top-line recovery.
Interest Costs and Inventory Drain Cash Reserves
Harvard Bioscience refinanced its debt in December 2025 at an effective interest rate near 18%, which requires the company to keep at least $3.0 million in cash. The high cost of that loan and ongoing factory transition spending are steadily shrinking its cash cushion.
- Cash on hand: $4.86 million, down from $6.50 million in June and $8.61 million in December
- Quarterly interest expense: $1.78 million, up 34.8% from $1.32 million a year ago
- Quarterly free cash flow: -$1.18 million by our math, including $0.93 million of equipment spending
- Net debt: $35.14 million, up 27.6% from $27.53 million a year ago
Interest expense alone ate up more than the company's $1.76 million of quarterly EBITDA excluding one-offs. Operations used $0.2 million of cash in the quarter as the business added $1.26 million to inventory ahead of moving factory lines, leaving just $1.86 million of buffer above the lender's $3.0 million cash floor.
What to watch: fourth-quarter operating cash flow and year-end cash balance. The company needs its seasonally strong fourth quarter to convert inventory into cash before term-loan repayments begin in December 2027.
Fourth-Quarter Plan Requires a Steep Margin Jump
Even after cutting its full-year profit target, management set a demanding target for the final three months of 2026. The fourth-quarter outlook calls for $23.7 million to $25.5 million in revenue and $3.8 million to $4.2 million in EBITDA excluding one-offs.
At the middle of those ranges, the US company must lift gross margin excluding one-offs by 2.9 percentage points from the third quarter to 60.0%, and more than double EBITDA from $1.76 million to $4.0 million. That implies a 16.3% EBITDA margin, slightly above last year's record 15.9% fourth quarter, despite the lower-margin China and distributor mix that hurt third-quarter profit.
What to watch: fourth-quarter gross margin excluding one-offs against the 59% to 61% target. Landing below 59% would show that distributor and product mix pressures are holding back the year-end profit jump.
Risks This Quarter Didn't Answer
Five standing concerns and watch items received no numbers in the third-quarter earnings release and await the conference call or quarterly filing.
- New product revenue share: not disclosed in the release; the call must show whether NPI held its 11% second-quarter share.
- US academic and government lab funding: no commentary on National Institutes of Health budget timing; regional tables in the filing will show Americas demand.
- Order backlog and customer advances: never quantified in dollars; the filing's contract liability note will show whether customer deposits stopped shrinking.
- Employee retention tax credit liability: $6.8 million potentially repayable on audit through 2029; other current liabilities rose to $26.1 million, awaiting footnote breakdown.
- Convertible debt and warrant overhang: $7.5 million of debt convertible at $10 and 170,000 warrants at $5 remain an open dilution risk.
💲 Other KPIs
Stockpiles rose for a third straight quarter, up 12.9% from $20.81 million at the end of 2025 and up 5.7% from June. The laboratory equipment maker is building extra inventory to prevent shipping delays while moving production lines out of its Massachusetts plant, which ties up working capital.
Uncollected customer bills edged up 2.8% from $14.50 million in the second quarter, but remain 7.0% below the $16.04 million balance at the end of 2025. Faster bill collection since year-end has helped offset some of the cash drained by rising factory inventory.
The weighted-average share count rose 2.4% from 4.46 million a year ago and 0.8% from the second quarter, adjusted for the March 2026 reverse split. Employee stock plans and warrant exercises continue to add shares while loan rules block buybacks.
🔮 Guidance
Cut. Management lowered its full-year profit growth plan by 6.5 percentage points at the middle of the range after holding it steady for three quarters. The group blamed higher sales of lower-margin cellular equipment and a bigger share of revenue coming from China and third-party distributors.
Unchanged. Harvard Bioscience kept the full-year sales target it raised last quarter. By our math, combining nine-month sales of $65.7 million with the fourth-quarter outlook middle of $24.6 million points to 4.3% full-year growth, right near the middle of the annual plan.
Unchanged. The US instrument maker held the annual margin range it lowered by one percentage point last quarter. Nine-month gross margin excluding one-offs stands at 57.9%, right at the middle of the full-year band.
New. The fourth-quarter plan calls for 3.6% growth from a year ago and a 10.8% jump from the third quarter at the $24.6 million middle of the range, by our math. Growth slows from 7.8% in the third quarter because the business faces a tough comparison against last year's $23.7 million fourth quarter.
New. The outlook calls for gross margin excluding one-offs to reach 60.0% at the middle of the range, up from 57.1% in the third quarter and 59.7% a year ago. Management expects seasonal fourth-quarter volume and new product demand to drive the 2.9-point sequential jump.
New. At the $4.0 million middle of the range, the plan requires a 5.7% rise from last year's $3.78 million fourth quarter and more than double the third quarter's $1.76 million, by our math.
❓ Key Questions
What share of third-quarter revenue came from new products?
Management previously cited an 11% revenue share for New Product Innovation in the second quarter as its primary margin driver. Without that figure in the release, investors cannot tell whether new instruments stalled or were simply outgrown by older cellular gear.
How will Harvard Bioscience rebuild its cash buffer above $3 million?
Cash fell by $1.65 million this quarter to $4.86 million as interest costs and inventory builds drained funds. That leaves less than $1.9 million of headroom above the loan agreement's $3.0 million minimum cash rule before principal repayments start in late 2027.
Did two more product lines leave Holliston in Q3?
Last quarter, executives promised to move two additional manufacturing lines out of the Holliston plant during the third quarter after moving two in the second. Hitting that milestone is critical to capturing $3 million of promised savings in 2027.
What drove the $4.2 million jump in other current liabilities?
Other current liabilities rose from $21.96 million at year-end to $26.13 million in September, while the company also carries a $6.8 million disputed tax credit refund in that line. Investors need to know whether restructuring accruals or overdue bills drove the increase.